Exact Sciences Corporation

NasdaqCM:EXAS Stock Report

Market Cap: US$10.3b

Exact Sciences Management

Management criteria checks 3/4

Exact Sciences' CEO is Kevin Conroy, appointed in Apr 2009, has a tenure of 15.83 years. total yearly compensation is $16.12M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $40.79M. The average tenure of the management team and the board of directors is 4.1 years and 5.3 years respectively.

Key information

Kevin Conroy

Chief executive officer

US$16.1m

Total compensation

CEO salary percentage6.5%
CEO tenure15.8yrs
CEO ownership0.4%
Management average tenure4.1yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

Nov 10
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Sep 25
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Exact Sciences: Cost Optimization And Product Strength

Aug 18

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Aug 14
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02
Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

CEO Compensation Analysis

How has Kevin Conroy's remuneration changed compared to Exact Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$214m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$16mUS$1m

-US$204m

Sep 30 2023n/an/a

-US$282m

Jun 30 2023n/an/a

-US$432m

Mar 31 2023n/an/a

-US$517m

Dec 31 2022US$14mUS$510k

-US$624m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$735m

Mar 31 2022n/an/a

-US$745m

Dec 31 2021US$15mUS$963k

-US$596m

Sep 30 2021n/an/a

-US$793m

Jun 30 2021n/an/a

-US$829m

Mar 31 2021n/an/a

-US$720m

Dec 31 2020US$20mUS$499k

-US$824m

Sep 30 2020n/an/a

-US$327m

Jun 30 2020n/an/a

-US$165m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$19mUS$792k

-US$213m

Sep 30 2019n/an/a

-US$216m

Jun 30 2019n/an/a

-US$221m

Mar 31 2019n/an/a

-US$219m

Dec 31 2018US$7mUS$696k

-US$175m

Compensation vs Market: Kevin's total compensation ($USD16.12M) is about average for companies of similar size in the US market ($USD12.45M).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.

CEO

Kevin Conroy (58 yo)

15.8yrs

Tenure

US$16,119,899

Compensation

Mr. Kevin T. Conroy served as Independent Director of SomaLogic, Inc. since September 1, 2021, until January 2022. Mr. Conroy had served as an Independent Director of Adaptive Biotechnologies Corporation s...

Leadership Team

NamePositionTenureCompensationOwnership
Kevin Conroy
Chairman of The Board & CEO15.8yrsUS$16.12m0.40%
$ 40.8m
Jake Orville
Executive VP & GM of Screeningno dataUS$3.67m0.0084%
$ 868.2k
Brian Baranick
Executive VP & General Manager of Precision Oncologyno dataUS$3.57m0.0071%
$ 737.1k
Aaron Bloomer
Chief Financial Officerless than a yearno datano data
Jorge Garces
Chief Science Officer3.8yrsno datano data
Nassar Nizami
Chief Information Officer2.1yrsno datano data
James Herriott
Senior VP3.1yrsno data0.0060%
$ 616.3k
Sarah Condella
Executive Vice President of Human Resources7.8yrsUS$2.71m0.042%
$ 4.4m
Graham Lidgard
Emeritus Chief Science Officer4.1yrsUS$4.21mno data
Ana Hooker
Chief Laboratory Officer9.6yrsUS$3.95mno data
Wayne Taylor
Head of Europe & Middle East and VPno datano datano data
Paul Limburg
Chief Medical Officer of Screening6.1yrsno datano data

4.1yrs

Average Tenure

50yo

Average Age

Experienced Management: EXAS's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kevin Conroy
Chairman of The Board & CEO15.9yrsUS$16.12m0.40%
$ 40.8m
Daniel Levangie
Independent Director14.6yrsUS$408.75k0.016%
$ 1.6m
Kimberly Popovits
Directorless than a yearno data0.0034%
$ 356.2k
D. Coward
Director2.2yrsUS$1.47m0.030%
$ 3.1m
Katherine Zanotti
Independent Director15.8yrsUS$406.25k0.038%
$ 3.9m
Michael Barber
Independent Directorless than a yearno data0.0032%
$ 331.4k
Paul Clancy
Independent Director3.9yrsUS$417.75k0.011%
$ 1.2m
Kathleen Sebelius
Independent Director5.9yrsUS$411.75k0.018%
$ 1.8m
Shacey Petrovic
Independent Director4.6yrsUS$401.25k0.013%
$ 1.3m
James Doyle
Lead Independent Director10.6yrsUS$442.75k0.030%
$ 3.1m

5.3yrs

Average Tenure

64yo

Average Age

Experienced Board: EXAS's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 05:06
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exact Sciences Corporation is covered by 47 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Bruce JacksonBenchmark Company